Clopiwin Plus 75 mg FC tablets.
PDF Leaflet Revision Date: 13 April 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Reduction of atherothrombotic events in adults with acute coronary syndrome.
Dosage (summary)
One tablet daily; no loading dose for patients >75 years.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- Warfarin
- NSAIDs
- SSRIs
- CYP2C19 inhibitors
Contraindications
- Hypersensitivity
- Active bleeding
- Severe hepatic impairment
- Thrombocytopenia
Common side effects
- Bleeding
- Dyspepsia
- Abdominal pain
- Bruising
Counselling Points
- Report unusual bleeding
- Avoid alcohol
- Inform healthcare providers before surgery
Serious warnings
- Thrombotic Thrombocytopenic Purpura (TTP)
- Increased bleeding risk
Important Disclaimer
The Clopiwin Plus 75 mg FC tablets. professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
